Clinical Trial Update: 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing 68Ga-RM2 PET/CT to 68Ga-PSMA-617 PET/CT for imaging in intermediate-risk prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-617
• 68Ga-RM2

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED